Crosstalk between Sodium–Glucose Cotransporter Inhibitors and Sodium–Hydrogen Exchanger 1 and 3 in Cardiometabolic Diseases
التاريخ
2021-11-24المؤلف
Al-Shamasi, Al-AnoodElkaffash, Rozina
Mohamed, Meram
Rayan, Menatallah
Al-Khater, Dhabya
Gadeau, Alain-Pierre
Ahmed, Rashid
Hasan, Anwarul
Eldassouki, Hussein
Yalcin, Huseyin Cagatay
Abdul-Ghani, Muhammad
Mraiche, Fatima
...show more authors ...show less authors
البيانات الوصفية
عرض كامل للتسجيلةالملخص
Abnormality in glucose homeostasis due to hyperglycemia or insulin resistance is the
hallmark of type 2 diabetes mellitus (T2DM). These metabolic abnormalities in T2DM lead to cellular
dysfunction and the development of diabetic cardiomyopathy leading to heart failure. New antihyperglycemic
agents including glucagon-like peptide-1 receptor agonists and the sodium–glucose
cotransporter-2 inhibitors (SGLT2i) have been shown to attenuate endothelial dysfunction at the
cellular level. In addition, they improved cardiovascular safety by exhibiting cardioprotective effects.
The mechanism by which these drugs exert their cardioprotective effects is unknown, although
recent studies have shown that cardiovascular homeostasis occurs through the interplay of the
sodium–hydrogen exchangers (NHE), specifically NHE1 and NHE3, with SGLT2i. Another theoretical
explanation for the cardioprotective effects of SGLT2i is through natriuresis by the kidney. This
theory highlights the possible involvement of renal NHE transporters in the management of heart failure.
This review outlines the possible mechanisms responsible for causing diabetic cardiomyopathy
and discusses the interaction between NHE and SGLT2i in cardiovascular diseases.
المجموعات
- الأبحاث [709 items ]
- الهندسة الميكانيكية والصناعية [1339 items ]